Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Adnan M. Nagrial

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0275-2479; OpenAlex author ID A5070415176. Sources: OpenAlex.

Their work

Papers
34 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
112
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: none · 2026: 2 papers

Papers 34

  1. Impact of postoperative pancreatic fistula (POPF) on long-term outcomes of patients who underwent pancreatic cancer resection: systematic review and meta-analy… Co-author DOI 10.1016/j.suronc.2026.102459↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. Chemotherapy and radiotherapy for advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd011044.pub3↗
  4. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
  5. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.igie.2024.06.005↗
  6. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  7. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  8. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
  9. Systematic Review of Single-Agent vs. Multi-Agent Chemotherapy for Advanced Pancreatic Adenocarcinoma in Elderly vs. Younger Patients. First author DOI 10.3390/cancers15082289↗
  10. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Co-author DOI 10.1016/j.esmoop.2021.100356↗
  11. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  12. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. Co-author DOI 10.1111/ajco.13721↗
  13. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  14. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  15. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  16. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  17. Chemotherapy and radiotherapy for advanced pancreatic cancer. First author DOI 10.1002/14651858.cd011044.pub2↗
  18. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Co-author DOI 10.1111/imj.13810↗
  19. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  20. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diseases6040103↗
  21. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  22. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  23. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  24. Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Co-author DOI 10.1074/mcp.m116.058313↗
  25. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Co-author DOI 10.1016/j.critrevonc.2015.07.007↗
  26. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  27. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. First author DOI 10.1158/1078-0432.ccr-15-0426↗
  28. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Co-author DOI 10.1200/jco.2013.51.5783↗
  29. Clinical and pathologic features of familial pancreatic cancer. Co-author DOI 10.1002/cncr.28863↗
  30. Adjuvant chemotherapy in elderly patients with pancreatic cancer. First author DOI 10.1038/bjc.2013.722↗
  31. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0048↗
  32. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  33. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  34. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Co-author DOI 10.1093/annonc/mdr561↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorraine A. Chantrill · 11 shared papers, 2012–2024 · strength 0.83
  2. Venessa T. Chin · 11 shared papers, 2012–2024 · strength 0.76
  3. Andrew Victor Biankin · 12 shared papers, 2012–2020 · strength 0.55
  4. Desmond Yip · 5 shared papers, 2015–2024 · strength 0.53
  5. Benjamin N. J. Thomson · 4 shared papers, 2019–2024 · strength 0.51
  6. Peter Gibbs · 4 shared papers, 2019–2024 · strength 0.51
  7. Belinda Lee · 4 shared papers, 2019–2024 · strength 0.51
  8. Marina Pajic · 11 shared papers, 2012–2020 · strength 0.51
  9. Mehrdad Nikfarjam · 4 shared papers, 2019–2024 · strength 0.48
  10. Nam Quoc Nguyen · 4 shared papers, 2014–2024 · strength 0.42
  11. Alison Lewis · 1 shared paper, 2023 · strength 0.39
  12. Jaswinder Singh Samra · 8 shared papers, 2012–2020 · strength 0.36
  13. Anthony James Gill · 8 shared papers, 2012–2020 · strength 0.36
  14. Matthew Burge · 3 shared papers, 2019–2024 · strength 0.36
  15. Angela S. Y. Chou · 7 shared papers, 2013–2020 · strength 0.34
  16. Harpreet Singh Wasan · 3 shared papers, 2013–2024 · strength 0.34
  17. Marion Harris · 3 shared papers, 2019–2023 · strength 0.33
  18. Niall Christopher Tebbutt · 3 shared papers, 2019–2023 · strength 0.33
  19. David Kuang-Fu Chang · 8 shared papers, 2012–2020 · strength 0.33
  20. Nick Pavlakis · 3 shared papers, 2015–2024 · strength 0.32
  21. Daniel Gerald Croagh · 2 shared papers, 2022–2024 · strength 0.31
  22. Yat Hang To · 2 shared papers, 2022–2024 · strength 0.31
  23. Adrian M. Fox · 2 shared papers, 2023–2024 · strength 0.29
  24. Amber L. Johns · 7 shared papers, 2012–2020 · strength 0.27
  25. Lee S. Kyang · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.